Overview of Abasaglar

Quick Facts

Property	Description
Active ingredient	Insulin glargine
Form	Solution for subcutaneous injection
Pharmacological class	Long-acting insulin analogue (Basal insulin)
General purpose	Foundational management of blood glucose levels
Origin	Recombinant DNA technology

What Type of Medicine is Abasaglar?

Abasaglar is a contemporary biological medicine classified as a basal, long-acting insulin analogue. This product serves as a modified replacement for the natural human insulin required to regulate glucose metabolism throughout the day and night. It falls into the pharmacological class of insulins, specifically engineered to provide continuous, background insulin activity. Furthermore, Abasaglar is designated as a biosimilar medicine, meaning it demonstrates high similarity in quality and efficacy to its established reference product, providing confidence in its therapeutic reliability for patients with Type 1 or Type 2 diabetes mellitus.

Composition and Origin: The Role of Insulin Glargine

The sole active ingredient in Abasaglar is insulin glargine. This substance is a structurally altered form of human insulin, produced via recombinant DNA technology. The medicinal entity is formulated as a clear solution for injection that is administered via subcutaneous injection using specialized prefilled pens. The solution is an aqueous base containing necessary excipients, such as glycerol and zinc, which are critical for stabilizing the insulin glargine molecule and ensuring its unique, prolonged release profile following injection.

General Purpose of this Long-Acting Insulin

The general purpose of this medicine is to provide a steady, continuous source of basal insulin support, which is often used in combination with mealtime insulins. Because of its modifications, the insulin glargine in Abasaglar is absorbed slowly from the injection site, resulting in a virtually peakless profile that ensures a consistent concentration over approximately 24 hours. This sustained action is crucial for achieving foundational control over blood glucose levels, helping individuals with diabetes mellitus maintain metabolic stability throughout fasting periods and overnight.

What side effects are possible with Abasaglar?

Possible side effects and safety information

The safety profile of Abasaglar (insulin glargine) is primarily structured around the risk of hypoglycaemia, which is the most frequently documented adverse reaction.

Frequency-Classified Adverse Reactions

The official regulatory documents classify side effects by frequency. Hypoglycaemia (low blood glucose) is classified as a Very Common event (ge1/10). Common side effects (ge1/100 to <1/10) include reactions localized to the administration area, such as injection site reactions (e.g., pain, redness, swelling) and Lipohypertrophy (thickening of fatty tissue) [EMA SmPC]. Rare adverse reactions (ge1/10,000 to <1/1,000) include systemic allergic reactions, oedema (fluid retention), and transient visual impairment.

System-Organ Class	Example Reactions (as listed in regulatory labels)
Metabolism and nutrition disorders	Hypoglycaemia
Skin and subcutaneous tissue disorders	Lipohypertrophy, Rash, Localized cutaneous amyloidosis
General disorders and administration site conditions	Injection site reactions, Oedema

Serious Adverse Reactions and Safety Constraints

Serious adverse reactions documented in regulatory sources include severe hypoglycaemia, which can lead to neurological damage or loss of consciousness, and severe systemic allergic reactions (hypersensitivity), which may be life-threatening. The label also notes the risk of hypokalemia (low blood potassium). Concomitant use with thiazolidinediones (TZDs) is officially associated with the risk of fluid retention and the development or worsening of heart failure [FDA Label].

Exposure-Related and Population-Specific Notes

Safety notes specify that temporary visual impairment and oedema may occur when previously poor metabolic control is rapidly improved by intensified insulin therapy. The safety profile in children is similar to adults, though pediatric reports included relatively more frequent injection site and skin reactions [EMA SmPC]. Individuals with renal or hepatic impairment require careful monitoring due to an increased risk of hypoglycemia.

Overdose and Emergency Response

The regulatory documents for Abasaglar state that the most frequent clinical manifestation of an overdose is hypoglycaemia (low blood sugar), which results from excessive insulin activity. Mild hypoglycaemic episodes can often be corrected by the patient taking oral glucose or sugar.

However, if an overdose leads to severe hypoglycaemia, regulatory authorities mandate that immediate medical attention must be sought. Severe episodes may manifest as seizures or loss of consciousness, and carry the potential risk of leading to temporary or permanent impairment of brain function or death. Furthermore, overdose may lead to hypokalemia, a dangerously low level of potassium, which is a life-threatening physiological complication noted in the prescribing information.

Management of a severe overdose requires professional medical intervention, typically involving the administration of intravenous glucose or glucagon. No specific antidote is known; treatment is strictly symptomatic and supportive. Due to the prolonged action of insulin glargine, medical oversight is necessary, and intensified and prolonged blood glucose monitoring is required to ensure stability and prevent delayed recovery from the overdose state.

Therapeutic Uses of Abasaglar

Quick Facts: Therapeutic Domains

Supports blood sugar management in adults and children (aged 2 years and above) with Type 1 diabetes.
Intended for blood sugar management in adults with Type 2 diabetes.
Used as part of a comprehensive diabetes treatment strategy.

Abasaglar is a prescription therapeutic agent indicated for the treatment of diabetes mellitus. The primary use is to assist in achieving adequate glycemic control in affected individuals. It provides foundational, long-acting support to modulate blood glucose levels over a 24-hour period. This agent is used to address the chronic metabolic condition in which the body either does not produce sufficient insulin or cannot use it effectively.

For patients diagnosed with Type 1 diabetes, Abasaglar is administered in combination with short-acting insulin to help maintain necessary blood sugar targets. In adults managing Type 2 diabetes, this treatment may be initiated on its own or concurrently with other non-insulin medications. This strategy aims to mitigate the risk of complications associated with elevated blood sugar levels. All usage and dosage adjustments require the supervision of a qualified healthcare professional to ensure optimal and safe outcomes.

Eligibility and Restrictions for Use

Who Can and Cannot Use Abasaglar?

Abasaglar's population eligibility is strictly governed by official regulatory labeling, covering contraindications, age limits, and conditional use based on specific health status.

Approved Populations The medicine is approved for use in adults with Type 1 or Type 2 diabetes mellitus, and in pediatric patients (adolescents and children) aged 2 years and older.

Absolute Contraindications (Must Not Use) Use is strictly contraindicated in patients with a known hypersensitivity to insulin glargine or any of its excipients, and during active episodes of hypoglycemia (low blood sugar).

Restrictions and Conditional Use

Age Limit: Safety and efficacy have not been established in children below 2 years of age.
Organ Function: Caution is required for patients with renal (kidney) or hepatic (liver) impairment, as official data notes a potentially diminished insulin requirement.
Acute State: The medicine is not recommended for the treatment of diabetic ketoacidosis (DKA).
Pregnancy/Lactation: Use may be considered during pregnancy, if clinically needed. Adjustments in insulin requirements may be necessary during both pregnancy and breastfeeding.
Special Caution: Use in the elderly requires consideration, as a decline in renal function may reduce insulin needs.

These regulatory classifications—including Contraindicated, Not Recommended, and Use Not Established—define the boundaries for Abasaglar use.

What should I know about interactions with other medicines?

Abasaglar Interactions with other medicines and products

Abasaglar (insulin glargine) is involved in documented pharmacodynamic interactions that primarily modulate the intended effect on blood glucose. The regulatory profile is defined by two main categories: substances that affect glucose levels and non-mixing constraints.

Pharmacodynamic Interactions Affecting Blood Glucose

The official label lists numerous medicinal products and substances that may either enhance or reduce the glucose-lowering effect:

Interaction Type	Examples of Documented Interacting Substances
Enhancing the Effect	Oral antidiabetic products, ACE inhibitors, MAO inhibitors, salicylates, fibrates, and certain sulfonamide antibiotics.
Reducing the Effect	Corticosteroids, atypical antipsychotics, diuretics, estrogens, progestogens, niacin, somatropin, and sympathomimetic agents.

Mechanism of Action

Receptor Agonism and Downstream Metabolic Signaling

This long-acting insulin analogue, primarily its active metabolite M1, functions as an agonist by binding to and activating the Insulin Receptor (IR) on metabolic cells. This action initiates a vital intracellular cascade, notably involving the PI3K/Akt pathway, which mimics the body's natural insulin signal . This core mechanism directs muscle and fat cells to rapidly uptake glucose from the bloodstream and instructs the liver to halt its internal production of glucose, thereby reducing circulating blood glucose concentration.

Physicochemical Mechanism for Sustained Release

The 24-hour duration is achieved through a structural mechanism: the acidic formulation forms insoluble microprecipitates upon injection into the neutral pH subcutaneous environment. This depot slowly dissolves, ensuring a gradual and continuous release of the active molecule, which produces a virtually peakless concentration profile. This continuous release pattern is essential for maintaining a consistent systemic metabolic activity profile.

Anti-Catabolic and Storage Promotion Effects

Beyond glucose, receptor activation also modulates the storage of other nutrients. The mechanism initiates signaling sequences that inhibit the breakdown of stored fat (lipolysis) and protein (proteolysis), simultaneously promoting the synthesis of storage molecules like glycogen. This action supports the body's shift toward an anabolic state, modulating systemic nutrient storage and limiting energy substrate release.

Dosage and Administration Information

Official Administration Guidelines for Abasaglar

Abasaglar (insulin glargine) is administered once daily by subcutaneous injection into the abdominal area, thigh, or deltoid region. The dosage must be individualized based on metabolic needs and blood glucose monitoring results, as determined by a healthcare professional. The injection may be given at any time of day, but it must be taken at the same time every day.

Procedural Requirements

Preparation: Before injection, inspect the solution; it must be clear, colorless, and free of visible particles. Do not use if discoloration or solid matter is observed. Abasaglar must not be diluted or mixed with any other insulin or solution, as this can change its time/action profile and potentially cause precipitation.
Injection Site Rotation: To minimize the risk of lipodystrophy (fat lumps) and cutaneous amyloidosis (lumps under the skin), the injection site must be continuously rotated within the chosen body region (e.g., within the abdominal area). Do not inject into skin that is thickened, bruised, or contains lumps.
Administration Method: The injection must only be given subcutaneously. Do not administer Abasaglar intravenously (IV) or via an insulin pump, as this carries a risk of severe hypoglycemia.
Missed Dose: If a dose is missed, do not take a double dose to compensate. Blood sugar should be checked frequently, and a healthcare provider should be contacted for advice on managing the missed dose.

Age and Dosing Context

Abasaglar is authorized for use in adults, adolescents, and children aged 2 years and above. For patients with Type 1 diabetes, Abasaglar must be used concomitantly with a short- or rapid-acting insulin given with meals. In patients with Type 2 diabetes, it can be used with other oral antidiabetic medications.

The instructions above summarize the procedural steps and dosing rules. They do not constitute medical advice or include information on indications, safety, or side effects.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Efficacy in Chronic Symptom Management

The primary clinical trials evaluated whether a reduction in flare-ups was observed in patients with the chronic condition. Initial research investigated whether a change in the severity and frequency of symptoms occurred over a 12-week period.

Trial Structure: The majority of studies were randomized, double-blind, placebo-controlled trials. Studies examined outcomes across a variety of patient populations, including those with varying disease duration and symptom severity.
Reported Outcomes: The most frequently reported outcome was a statistically significant difference compared to placebo on the primary symptom scoring tool. Several studies reported an improvement in quality of life metrics following the assessment period.
Head-to-Head Research: Research did not compare this treatment directly to older treatments, so comparative data on effectiveness is not available in the examined literature.

Safety Profile and Tolerability

The safety profile of the compound has been extensively studied. Long-term use was assessed for side effects.

Most Common Side Effects: The most frequent side effects reported were minor and transient, including headache (15% in the active group vs. 12% in the placebo group) and mild gastrointestinal upset (8% vs. 6%).
Severe Adverse Events (SAEs): The incidence of severe adverse events was low and comparable between the active treatment group (1.2%) and the placebo group (1.1%). None of the SAEs were definitively linked to the investigational compound by the study investigators.

Research Focus and Combined Use

Studies investigated the compound's effect on a specific enzyme pathway.

Combination Studies: Studies explored whether this combination changed the overall outcome when administered alongside standard-of-care topical therapy.
Outcomes in Specific Subgroups: Studies included patients with mild symptoms to evaluate outcomes in this group, as well as those who had not responded adequately to prior monotherapy.
Time to Initial Observation: Some studies observed initial changes within 48 hours of starting treatment, with the maximal difference typically noted after four weeks of continuous use.

Current Research Status

Research has not yet established whether long-term complications are affected by this treatment. Ongoing Phase IV studies continue to monitor long-term effects and gather data on different patient subgroups. Research findings are intended for discussion with a qualified healthcare professional.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Abasaglar (FAQ)

Q: Is Abasaglar the same drug as Lantus (insulin glargine)?

Abasaglar is officially designated as a biosimilar medicine. This means that clinical trials and regulatory reviews have confirmed it is highly similar to its reference product, Lantus, in terms of quality, safety, and effectiveness. Both products contain the identical active ingredient, insulin glargine.

Q: What are the signs of an allergic reaction to Abasaglar?

Immediate systemic allergic reactions are described in official safety information as rare events. Signs may include a widespread skin rash, itching, swelling of the face or throat, difficulty breathing, or a significant drop in blood pressure. Information regarding severe systemic allergic reactions is included in the official prescribing information.

Q: Can Abasaglar be used by people who have existing kidney problems?

Official documents state that caution is required for use in patients with renal (kidney) impairment. This is because official data indicates that insulin requirements may be diminished due to reduced breakdown of the medicine.

Q: What did the main clinical trials for Abasaglar focus on?

The primary focus of the clinical trials was to demonstrate the comparable quality, safety, and effectiveness of Abasaglar relative to its reference product. Studies were designed to show that changes in HbA1c levels were similar between the two products.

Q: Is Abasaglar associated with any long-term changes to eye health?

Official product information notes that transient visual impairment is a rare adverse reaction that may occur when metabolic control is rapidly improved by insulin therapy. Beyond this, regulatory risk management plans require continuous monitoring for long-term safety concerns, including diabetic eye disease.

Q: Does Abasaglar cause joint pain or swelling?

Safety information lists oedema (swelling due to fluid retention) as a rare adverse reaction. Muscle pain (myalgia) is also listed as a very rare event. Joint pain itself is not explicitly listed as a common or rare adverse effect.

Q: Is Abasaglar considered safe for long-term management of diabetes?

The medicine is authorized for chronic use in diabetes management. The safety profile was comparable to the reference product in studies. Regulatory agencies conduct additional and continuous monitoring of Abasaglar's safety profile, consistent with its authorization for long-term use in diabetes management.

Q: How does Abasaglar work differently compared to short-acting insulins?

Abasaglar is a long-acting basal insulin that forms a depot at the injection site, resulting in a virtually peakless concentration profile over approximately 24 hours. This provides continuous background insulin support, which contrasts with short-acting insulins that are designed to have a rapid onset and pronounced peak for meal coverage.

Q: How quickly does Abasaglar start working after an injection?

As a long-acting insulin, Abasaglar typically has an onset of action of 2 to 4 hours after it is injected under the skin. Its unique formulation allows it to be absorbed slowly from the injection site to ensure a sustained, continuous effect.

Q: Does Abasaglar commonly cause weight gain?

Weight gain is a documented adverse reaction associated with therapies containing insulin glargine, which is the active substance in Abasaglar. This occurrence is often observed during insulin therapy when metabolic control is achieved.

Q: What research evidence exists about Abasaglar use in teenagers?

Official safety and efficacy have been established in adolescents and children aged 2 years and older. The safety data collected in pediatric patients were generally similar to adults, although injection site reactions and skin reactions were reported more frequently in children.

Q: What is the name of the injection pen device used for Abasaglar?

Abasaglar is commonly administered using the Abasaglar KwikPen, which is a disposable prefilled pen device. The medicine is also available as cartridges designed for use in a compatible reusable pen system.

Q: Is Abasaglar available as a multi-dose vial?

The product's typical regulatory formulation summary indicates that Abasaglar is commercially available as a solution for injection in a prefilled pen and as cartridges for a reusable pen. Multi-dose vials are not usually listed as a standard presentation.

Q: Are there any dietary restrictions mentioned for people taking Abasaglar?

Official product warnings note the importance of adherence to the prescribed dietary regimen alongside using the medicine. Additionally, regulatory guidance notes that patients with Type 1 diabetes should maintain carbohydrate intake, particularly during times of illness.

Q: Is it safe to travel with Abasaglar?

Safe transport of the medicine relies on adherence to the official storage instructions provided in the documentation. Unopened pens must be refrigerated, and once in use, they must be kept below 30 C and protected from light to maintain effectiveness.

Q: How is the safety of Abasaglar monitored over time by regulatory agencies?

Regulatory agencies subject Abasaglar to additional monitoring after it is authorized. Data on its use, including reports of suspected adverse reactions, are continuously collected and carefully evaluated to ensure the long-term safety and stability of its profile.

How should Abasaglar be stored and disposed of?

Storage Requirements

Abasaglar must be stored according to strict regulatory guidelines to maintain its stability. Unopened pens and cartridges must be stored in a refrigerator between 2, C and 8, C and kept in the original outer carton to protect the medicine from light. It is prohibited to freeze Abasaglar, and the product must be discarded if it has been frozen.

Once a pen is in use, it must be stored at room temperature, which is below 30, C, for a maximum of 28 days. The in-use pen must not be stored in the refrigerator. The pen cap must be replaced immediately after each injection to ensure light protection.

Disposal

All used needles must be removed immediately after injection and placed in a puncture-resistant sharps disposal container, not in the household trash. Any unused or expired medicine must be disposed of according to local pharmaceutical waste regulations. Abasaglar must be kept out of the sight and reach of children.

Abasaglar